Rituximab treatment in non-lupus full-house nephropathy: A case report
Non-lupus full-house nephropathy describes a pattern of “full-house” immunofluorescence on renal biopsy in the absence of clinical or serologic markers for systemic lupus erythematosus. It is a rare disease with a broad range of etiologies, including idiopathic, secondary, or a prodrome of systemic...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-05-01
|
| Series: | SAGE Open Medical Case Reports |
| Online Access: | https://doi.org/10.1177/2050313X251333979 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850032231454605312 |
|---|---|
| author | Caroline Gee Dao Le Matthew D. Nguyen Anthony Sisk Ramy Hanna |
| author_facet | Caroline Gee Dao Le Matthew D. Nguyen Anthony Sisk Ramy Hanna |
| author_sort | Caroline Gee |
| collection | DOAJ |
| description | Non-lupus full-house nephropathy describes a pattern of “full-house” immunofluorescence on renal biopsy in the absence of clinical or serologic markers for systemic lupus erythematosus. It is a rare disease with a broad range of etiologies, including idiopathic, secondary, or a prodrome of systemic lupus erythematosus. Current treatment options are lacking, with mixed results in the literature for varied immunosuppressive regimens. Rituximab, a selective anti-CD20 B-cell monoclonal antibody, has shown success in immune-complex mediated glomerular diseases but has not been commonly used or studied in non-lupus full-house nephropathy. Here, we present a case of non-lupus full-house nephropathy that was refractory to first-line immunosuppressants, in which two rounds of rituximab treatment achieved a positive response. This case emphasizes the need for systemic analysis of rituximab use in non-lupus full-house nephropathy, particularly given its mixed etiologies and presentations. |
| format | Article |
| id | doaj-art-99e7f9e04eb94e5d8da66b8502ea412b |
| institution | DOAJ |
| issn | 2050-313X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | SAGE Open Medical Case Reports |
| spelling | doaj-art-99e7f9e04eb94e5d8da66b8502ea412b2025-08-20T02:58:43ZengSAGE PublishingSAGE Open Medical Case Reports2050-313X2025-05-011310.1177/2050313X251333979Rituximab treatment in non-lupus full-house nephropathy: A case reportCaroline Gee0Dao Le1Matthew D. Nguyen2Anthony Sisk3Ramy Hanna4Division of Nephrology, Hypertension and Kidney Transplantation, University of California, Irvine, CA, USADivision of Nephrology, Hypertension and Kidney Transplantation, University of California, Irvine, CA, USADivision of Nephrology, Hypertension and Kidney Transplantation, University of California, Irvine, CA, USADivision of Pathology and Laboratory Medicine, University of California, Los Angeles, CA, USADivision of Nephrology, Hypertension and Kidney Transplantation, University of California, Irvine, CA, USANon-lupus full-house nephropathy describes a pattern of “full-house” immunofluorescence on renal biopsy in the absence of clinical or serologic markers for systemic lupus erythematosus. It is a rare disease with a broad range of etiologies, including idiopathic, secondary, or a prodrome of systemic lupus erythematosus. Current treatment options are lacking, with mixed results in the literature for varied immunosuppressive regimens. Rituximab, a selective anti-CD20 B-cell monoclonal antibody, has shown success in immune-complex mediated glomerular diseases but has not been commonly used or studied in non-lupus full-house nephropathy. Here, we present a case of non-lupus full-house nephropathy that was refractory to first-line immunosuppressants, in which two rounds of rituximab treatment achieved a positive response. This case emphasizes the need for systemic analysis of rituximab use in non-lupus full-house nephropathy, particularly given its mixed etiologies and presentations.https://doi.org/10.1177/2050313X251333979 |
| spellingShingle | Caroline Gee Dao Le Matthew D. Nguyen Anthony Sisk Ramy Hanna Rituximab treatment in non-lupus full-house nephropathy: A case report SAGE Open Medical Case Reports |
| title | Rituximab treatment in non-lupus full-house nephropathy: A case report |
| title_full | Rituximab treatment in non-lupus full-house nephropathy: A case report |
| title_fullStr | Rituximab treatment in non-lupus full-house nephropathy: A case report |
| title_full_unstemmed | Rituximab treatment in non-lupus full-house nephropathy: A case report |
| title_short | Rituximab treatment in non-lupus full-house nephropathy: A case report |
| title_sort | rituximab treatment in non lupus full house nephropathy a case report |
| url | https://doi.org/10.1177/2050313X251333979 |
| work_keys_str_mv | AT carolinegee rituximabtreatmentinnonlupusfullhousenephropathyacasereport AT daole rituximabtreatmentinnonlupusfullhousenephropathyacasereport AT matthewdnguyen rituximabtreatmentinnonlupusfullhousenephropathyacasereport AT anthonysisk rituximabtreatmentinnonlupusfullhousenephropathyacasereport AT ramyhanna rituximabtreatmentinnonlupusfullhousenephropathyacasereport |